
19/08/2025
It was fantastic to see so many ALLG members presenting their research at the 2025 International Conference on Malignant Lymphoma (ICML), including important updates on our lymphoma trials NHL39 POLAR BEAR, NHL37 GOlDiLOX and HD10. There was a sense of collaboration and momentum as we deepened discussions with leading international research groups and industry partners to deliver access to better lymphoma treatments across Australia and New Zealand.
These engagements reflect ALLG's role as Australasia's only not-for-profit, collaborative blood cancer clinical trials group, driving progress in the treatment of leukaemia, lymphoma and related blood diseases through independent, investigator-initiated clinical trials.
ALLG are Global Leaders with Global Impact, with over 5 decades of designing and delivering leading clinical trials to over 15,000 patients. Every approved treatment today started with a clinical trial.
Visit allg.org.au to learn more about our research and how you can support the future of blood cancer treatments.